(CTMX) CytomX Therapeutics - Ratings and Ratios

CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development of conditionally activated biologics for oncology. The companys core technology platforms—Conditional Activation and Probody—enable the creation of localized therapies that minimize systemic toxicity and enhance efficacy. The Conditional Activation platform is designed to activate therapeutic proteins only within the tumor microenvironment, reducing off-tumor effects. The Probody platform leverages proprietary masking and activation technology to improve the therapeutic index of biologics, including cytokines and ADCs.

The companys pipeline includes CX-904, a T-cell-engaging bispecific antibody targeting EGFR and CD3, currently in Phase 1/2 trials for solid tumors; CX-2051, a conditionally activated ADC targeting EpCAM-expressing cancers, including colorectal cancer; and CX-801, a Probody cytokine based on interferon alpha-2b, being evaluated in combination with pembrolizumab. Additionally, CX-2029, a conditional ADC targeting CD71, and BMS-986288, a Probody version of ipilimumab, are in earlier stages of development.

CytomX has established strategic collaborations with major biopharma companies, including Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. The company also has a clinical trial collaboration and supply agreement with Merck to evaluate CX-801 in combination with KEYTRUDA. Founded in 2008 and headquartered in South San Francisco, California, CytomX is focused on advancing its pipeline of novel oncology therapeutics.

Ticker Symbol: CTMX Exchange: NASDAQ Type: common stock Country Origin: United States GICS Sub Industry: Biotechnology

3-Month Forecast: Based on the current technical and fundamental data, CTMX is expected to experience continued volatility. The stock is trading below its 20-day and 50-day moving averages, with a last price of $0.62, indicating bearish momentum. The ATR of $0.06 suggests moderate price movement. However, the low forward P/E of 14.20 and P/S of 0.50 indicate potential upside if the company demonstrates progress in its clinical pipeline. Market participants should monitor trial results and collaboration updates for directional cues.